S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Abcam and Genedata Align on AI-Driven Antibody Development

By integrating the Genedata Biologics platform across its global R&D network, Abcam aims to streamline the production of roughly 500 new antibodies annually. The collaboration between the two Danaher subsidiaries focuses on digitizing complex workflows to accelerate the delivery of validated reagents to researchers worldwide.

Abcam and Genedata Align on AI-Driven Antibody Development
Photo: Bio & News

The deployment of Genedata’s enterprise software at Abcam facilities in the UK, China, and the US establishes a unified digital backbone for the company’s development pipeline. By centralizing data from cross-functional teams, the platform enables automated tracking of sample histories and characterization data, replacing fragmented processes with a structured environment designed for AI-powered discovery.

Kaveh Kahen, President of Abcam, noted that the infrastructure provides the automation and connectivity necessary to scale operations in response to growing global demand. For Othmar Pfannes, President of Genedata, the partnership represents a strategic effort to generate actionable scientific insights at scale, ultimately reducing the time required to move from early discovery to high-quality research outcomes.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!